不同肝病患者血清自身抗体谱阳性率调查*

doi:10.3969/j.issn.1672-5069.2023.03.017

Abstract

Abstract: Objective The aim of this study was to investigate the prevalence of serum autoantibody spectrums in patients with different liver diseases. Methods 92 patients with autoimmune liver diseases (ALD), including autoimmune hepatitis (AIH) in51 cases, primary biliary cholangitis (PBC) in 27 cases and primary sclerosing cholangitis (PSC) in 14 cases, chronic hepatitis B(CHB) in 61 cases and chronic hepatitis C (CHC) in 15 cases, nonalcoholic steatohepatitis (NASH) in 34 cases, drug-induced liver injury (DILI) in 27 cases and healthy persons in 68 cases were recruited in our hospital between March 2019 and March 2022, and serum autoimmune antibody spectrum was detected by immunoblotting. Results The positive rates of anti-mitochondrial antibody M2 subtype (AMA-M2), anti-soluble liver antigen/anti-liver pancreas antibody (SLA/LP), anti-liver kidney microsomal antibody type I (LKM-1), anti-transmembrane glycoprotein 210 (gp210), anti-liver cytosol antigen type I (LC-1), anti-3E, anti-promyelocytic leukemia (PML) and anti-RO-52 in patients with ALD 23.9%,13.0%,33.7%,19.6%,26.1%, 33.7%, 23.9% and 55.4%, significantly higher than in patients with other liver diseases (P<0.05); the positive rates of anti-SLA/LP, anti-LKM-1 and anti-LC-1 in patients with AIH were much higher than in patients with PBC or in patients with PSC(P<0.05), while the positive rates of AMA-M2, anti-gp210 and anti-3E in patients with PBC were much higher than in patients with AIH or in those with PSC(P<0.05); the positive rates of serum anti-LKM-1 and anti-LC-1 in 24 patients with AIH type Ⅱ were 100.0% and 66.7%, much higher than 19.0% and 19.0% (P<0.05) in 21 patients with AIH type Ⅰ or 16.7% and 33.3% (P<0.05) in 6 patients with AIH type Ⅲ, while the positive rate of serum anti-SLA/LP in patients with AIH type Ⅲ was 83.3%, much higher than 9.5% in patients with AIH type Ⅰ or 16.7% in patients with AIH type Ⅱ(P<0.05). Conclusion The detection of serum autoantibody spectrums is a key approach for the diagnosis and clinical classification of patients with ALD, and why they appear, though at low prevalence, in patients with other liver diseases needs further investigation.

Key words: Autoimmune liver diseases, Autoimmune antibody spectrum, Diagnosis

Sun Cui, Cao Linlin, Liu Jun. Prevalence of serum autoantibody spectrums in patients with different liver diseases[J]. Journal of Practical Hepatology, 2023, 26(3): 368-371.

References

[1] 龙梅,王丽旻,朱莉,等.自身免疫性肝炎患者临床和肝组织病理学特征.实用肝脏病杂志,2020,23(1):142-143.
[2] Liwinski T, HeinemannM, Schramm C. The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts. Semin Immunopathol, 2022, 44(4):485-507.
[3] Mahmud N, Forde KA. Autoimmunity in indeterminate etiologies of acute liver failure: Is this autoimmune liver disease or an autoimmune phenotype to drug toxicity? Liver Transpl, 2020, 26(6):743-745.
[4] Cha HJ, Hwang J, Lee LE, et al. The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease. PLoS ONE, 2021, 16(1):e0244950.
[5] 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗指南(2021年).中华内科杂志,2021,60(12):1038-1049.
[6] 马雄.自身免疫性肝病的诊治:从共识到指南.中华肝脏病杂志,2016,24(1):3-4.
[7] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[8] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2019年更新版.实用肝脏病杂志,2020,23(1):S33-52.
[9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[10] Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int, 2021, 15(2):258-282.
[11] 中国医师协会风湿免疫科医师分会自身抗体检测专业委员会,国家风湿病数据中心,国家皮肤与免疫疾病临床医学研究中心.自身免疫性肝病相关自身抗体检测的临床应用专家共识.中华内科杂志,2021,60(7):619-625.
[12] 冯静,罗思剑,李靖,等.不同类型自身免疫性肝病患者肝组织炎症因子表达的变化.实用肝脏病杂志,2020,23(3):356-359.
[13] Raja G, Gupta H, Gebru YA, et al. Recent advances of microbiome-associated metabolomics profiling in liver disease: principles, mechanisms, and applications. Int J Mol Sci, 2021, 22(3):e1160.
[14] Wang CR, Wu IC, Tsai HW. An overlap syndrome involving systemic lupus erythematosus and autoimmune hepatitis in a patient receiving a living-donor liver transplantation. Lupus, 2020, 29(1):96-97.
[15] Jagdish RK, Sarin SK, Choudhury A, et al. THU-012-prevalence of autoimmune liver disease related autoantibodies in various non autoimmune liver diseases. J Hepatol, 2019, 70(1):e165-e166.
[16] Ma Y, Su H, Yuksel M, et al. Human leukocyte antigen profile predicts severity of autoimmune liver disease in children of European ancestry. Hepatology, 2021, 74(4):2032-2046.
[17] Ellinghaus D. How genetic risk contributes to autoimmune liver disease. Semin Immunopathol, 2022, 44(4):397-410.
[18] Biewenga M, Farina Sarasqueta A, Tushuizen ME, et al. The role of complement activation in autoimmune liver disease. Autoimmun Rev, 2020, 19(6):102534.
[19] Laschtowitz A, Zachou K, Lygoura V, et al. Patients with autoimmune hepatitis and liver cirrhosis have disease activity despite normal transaminases. J Hepatol, 2020, 73(2):S87-S88.
[20] Tanaka A, Kono H, Leung PSC, et al. Recurrence of disease following organ transplantation in autoimmune liver disease and systemic lupus erythematosus. Cell Immunol, 2019, 347(1):104021.
[21] 张洋.自身免疫性肝炎患者血清抗延胡索酸水合酶抗体检测及其临床意义探讨.实用肝脏病杂志,2020,23(4):512-515.
[22] Gomes NBN, Torres US, Ferraz MLCG, et al. Autoimmune hepatitis in practice, from diagnosis to complications: What is the role of imaging? A clinicoradiological review. Clin Imaging, 2021, 74(1):31-40.

Prevalence of serum autoantibody spectrums in patients with different liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tao Zhenzhen, Wang Yongli, Sun Hongyan, et al.. Comparison of different Young's modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 328-331.
[2]	Zhao Jing, He Xiubo, Chen Jinhuan. Early diagnosis of significant liver fibrosis by liver shear wave elastography and GGT/PLT ratio in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 332-335.
[3]	Zhao Lingling, Wang Beibei, Yao Yongli, et al.. Serum resistin and triacylglycerol glucose index in patients with T2DM and non-alcoholic fatty liver: their combination for progressive fibrosis [J]. Journal of Practical Hepatology, 2023, 26(3): 356-359.
[4]	Zhu Lin, Chen Yang, Yang Qing, et al.. Diagnostic performance of ultrasound elastography in evaluation of liver fibrosis in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 360-363.
[5]	Liu Lingyu, Wang Wei, Tang Jiamei. Application of ultrasound three-dimensional speckle tracking imaging in the early diagnosis of cirrhotic cardiomyopathy in patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(3): 400-403.
[6]	Shi Lei, An Ziming, Feng Qin. Clinical implication of serum AFP, AFP-L3% and PIVKA-II in early diagnosing and predicting prognosis of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(3): 404-407.
[7]	Chen Qiquan, Li Xiaoting, Yang Xunyi, et al.. Diagnostic efficacy of liver contrast-enhanced ultrasound, shear wave elastography and contrast-enhanced CT scan in patients with occupying lesions in liver [J]. Journal of Practical Hepatology, 2023, 26(3): 408-411.
[8]	Lin Yongzhu, Shi Hongyuan, Mu Xihu. Diagnosis of small primary liver cancer under the background of liver cirrhosis by dual-source CT hepatic artery three-phase scanning and enhanced perfusion scanning [J]. Journal of Practical Hepatology, 2023, 26(3): 412-415.
[9]	Duan Haishan, Jiang Li, Tian Qingqing, et al.. Differential diagnosis of patients with hepatocellular carcinoma and hepatic hemangioma by contrast-enhanced ultrasonography [J]. Journal of Practical Hepatology, 2023, 26(3): 420-423.
[10]	Bai Tingting, Liu Yuyi, Chen Dongfeng. Diagnosis and differential diagnosis of patients with hepatic vascular diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 153-155.
[11]	Deng Yuting, Zhou Junying. Budd-Chiari syndrome:Current state of the art [J]. Journal of Practical Hepatology, 2023, 26(2): 156-159.
[12]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[13]	Deng Kexin, Luo Hongchun. Evaluation of bacterial infection by common hematological indexes in patients with acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2023, 26(2): 242-245.
[14]	Shu Kaifeng, Mi Chun, Liu Weiwei, et al.. Diagnostic performance of high-frequency and color Doppler ultrasonography in judging the benign and malignant gallbladder polyps [J]. Journal of Practical Hepatology, 2023, 26(2): 286-289.
[15]	Ma Li, Gao Lili, Duan Xuefei. Diagnosis and treatment of patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome [J]. Journal of Practical Hepatology, 2023, 26(2): 301-304.